Elanco stock: Elanco announces November 6 results for Elanco stock

Published on 10/22/2026 at 22:57 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue reached USD 1.37 billion, up 10.20 percent year over year. Elanco stock costs EUR 20.21 on October 22, 2026.

Reporting date and revenue

Elanco's third-quarter 2026 results are scheduled for November 6, 2026.
Second-quarter revenue reached USD 1.37 billion, up 10.20 percent year over year.
Elanco stock costs EUR 20.21 at Lang & Schwarz on October 22, 2026 at 10:56 p.m. CEST; the NYSE session closed at USD 22.55 on October 21, 2026.
Elanco's market capitalization was USD 11.3 billion on October 22, 2026.

ELAN, US28414H1032, Illustration mit AI erstellt.

Elanco Animal Health (US28414H1032) has scheduled its third-quarter 2026 results for November 6, 2026, giving investors a clear date for the next operating update. The company also reported USD 1.37 billion in second-quarter revenue, up 10.20 percent year over year, while Elanco stock was trading at EUR 20.21 at Lang & Schwarz on October 22, 2026 at 10:56 p.m. CEST.

November 6 sets the next test

According to Elanco Animal Health, the third-quarter 2026 earnings call is scheduled for November 6, 2026, at 8:00 a.m. Eastern Time. The company entered the quarter with revenue guidance of USD 1.195 billion to USD 1.22 billion and adjusted earnings per share guidance of USD 0.19 to USD 0.22.

Revenue growth remains the key figure

Elanco's second-quarter revenue was USD 1.368 billion, according to the company's earnings-call transcript carried by Yahoo Finance on August 5, 2026. Organic constant-currency revenue grew 8.00 percent, adjusted EBITDA reached USD 288 million, and adjusted earnings per share rose 31.00 percent year over year to USD 0.34.

Price position and valuation

On the NYSE, Elanco last traded at USD 22.69 on October 22, 2026 at 4:00 p.m. EDT, up 0.62 percent from USD 22.55. The 52-week range was USD 19.40 to USD 27.98, placing the latest home-market price USD 5.29 below the high and USD 3.29 above the low. Market capitalization stood at USD 11.3 billion on October 22, 2026.

What changes before results?

Jefferies downgraded Elanco from Buy to Hold and cut its target from USD 31.00 to USD 24.00 in a report dated October 20, 2026, as reported by MarketBeat. The new target is 5.77 percent above the USD 22.69 NYSE price, leaving the November report as the next concrete test for the company's growth and margin outlook.

Comparison with peers

Elanco: plus 0.62 percent, price-to-earnings ratio minus 56.72, market capitalization USD 11.3 billion.

Zoetis (NYSE, USD): plus 2.96 percent, price-to-earnings ratio 13.51, market capitalization USD 33.9 billion.

IDEXX Laboratories (Nasdaq, USD): plus 2.40 percent, price-to-earnings ratio 40.14, market capitalization USD 44.6 billion.

Investor view before November 6

Elanco combines a dated results event with a second-quarter revenue increase and raised full-year adjusted earnings per share guidance of USD 1.10 to USD 1.16. The valuation gap to its larger animal-health peers remains visible, but the next reported quarter will determine whether innovation revenue and margin gains continue to offset pricing pressure.

Elanco stock was trading at EUR 20.21 at Lang & Schwarz on October 22, 2026 at 10:56 p.m. CEST; the NYSE session had last traded at USD 22.69 on October 22, 2026 at 4:00 p.m. EDT. The further course of trading is shown by the continuously updated real-time quote of Elanco stock.